Recombinant Rat TRANCE/RANK L/TNFSF11 Protein, CF

Recombinant Rat Trance/RANK L/TNFSF11 (Catalog # 9366-TN/CF)Induces Osteoclast Differentiation of the RAW 264.7 Mouse Monocyte/MacrophageCell Line. The ED50 for this effect is2.5-15 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050R).

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat TRANCE/RANK L/TNFSF11 Protein, CF Summary

• Details of Functionality: Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED₅₀ for this effect is 2.5-15 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050R).
• Source: Chinese Hamster Ovary cell line, CHO-derived rat TRANCE/TNFSF11/RANK L protein
  Arg72-Asp318, with an N-terminal 6-His tag
• Accession #: XP_008769150
• N-terminal Sequence: His
• Protein/Peptide Type: Recombinant Proteins
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 29 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 33-38 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in NaH₂PO₄, NaCl and EDTA.
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat TRANCE/RANK L/TNFSF11 Protein, CF

• CD254 antigen
• CD254
• ODF
• OPGL
• OPGLOPTB2
• Osteoclast differentiation factor
• Osteoprotegerin ligand
• RANK L
• RANKL
• RANKLreceptor activator of nuclear factor kappa B ligand
• Receptor activator of nuclear factor kappa-B ligand
• sOdf
• TNF-related activation-induced cytokine
• TNFSF11
• TRANCE
• TRANCEODFhRANKL2
• tumor necrosis factor (ligand) superfamily, member 11
• tumor necrosis factor ligand superfamily member 11

Background

RANK L (receptor activator of NF-kappa B ligand), also called TRANCE (TNF-related activation-induced cytokines), OPGL (osteoprotegerin ligand), or ODF (osteoclast differentiation factor), is a 39-45 kDa type II transmembrane (TM) protein in the tumor necrosis factor family, designated TNFSF11 (1-5). RANK L, produced by osteoblasts and bone marrow stromal cells, is required for differentiation of osteoclasts and stimulates bone resorption (4, 6). It is also produced by activated T cells and augments dendritic cell stimulation; RANK L^-/- mice lack lymph nodes and have impaired thymocyte development (1-3, 6). The rat RANK Ligand cDNA encodes a type II transmembrane protein of 318 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 250 amino acids. The extracellular domain contains two potential N-linked glycosylation sites. Rat and human RANK Ligand and rat and mouse RANK Ligand share 83% and 95% amino acid identity respectively. RANK L can stimulate human osteoclast differentiation (4). Like most TNF family members, RANK L can form trimers (1). Soluble 31, 25 and 24 kDa forms of RANK L can be created by usage of alternate start sites at aa 74 or 146, or proteolytic cleavage by osteoblast- or stromal cell-derived ADAM10 (after aa 139) or MMP14 (aa 146), or bone metastatic prostate tumor-derived MT1-MMP (aa 146) (5, 7, 8). Both TM and soluble extracellular RANK L act by engaging RANK receptors and are antagonized by the decoy receptor, OPG (osteoprotegrin) (2, 5). In resting cells, the majority of RANK L is stored in secretory lysosomes (9). In mammary epithelia, RANK L is up-regulated by pregnancy hormones and is essential for the formation of a lactating mammary gland (10). In the brain, astrocyte RANK L mediates body temperature regulation (11). Pathologically, RANK L is thought to mediate post-menopausal osteoporosis, vascular calcification, progestin-induced breast cancer, cancer-induced bone disease, and osteopetrosis (in RANK L deficiencies) (12-16).

1. Leibbrandt, A. and J.M. Penninger 2008) Ann. N. Y. Acad. Sci. 1143:123.
2. Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
3. Anderson, D.M. et al. (1997) Nature 390:175.
4. Lacey, D.L. et al. (1998) Cell 93:165.
5. Hikita, A. et al. (2006) J. Biol. Chem. 281:36846.
6. Kong, Y-Y. et al. (1999) Nature 397:315.
7. Accession # NP_143026 and EAX08679.
8. Sabbota, A.L. et al. (2010) Cancer Res. 70:5558.
9. Aoki, S. et al. (2010) J. Bone Miner. Res. 25:1907.
10. Fata, J.E. et al. (2000) Cell 103:41.
11. Hanada, R. et al. (2009) Nature 462:505.
12. Osako, M.K. et al. (2010) Circ. Res. 107:466.
13. Schramek, D. et al. (2010) Nature 468:98.
14. Gonzalez-Suarez, E. et al. (2010) Nature 468:103.
15. Dougall, W.C. and M. Chaisson (2006) Cancer Metastasis Rev. 25:541.
16. Sobacchi, C. et al. (2007) Nat. Genet. 39:960.

Publications for TRANCE/TNFSF11/RANK L (9366-TN/CF)(4)

Publications using 9366-TN/CF

• B Meng, B Yang, Y Qu, Y Liu, D Wu, C Fu, Y He, X Chen, C Liu, X Kou, Y Cao Dual Role of Interleukin-20 in Different Stages of Osteoclast Differentiation and Its Osteoimmune Regulation during Alveolar Bone Remodeling International Journal of Molecular Sciences, 2023-02-14;24(4):. 2023-02-14 [PMID: 36835229] (Bioassay, Rat)
• Y Liu, Y Ai, X Sun, B Meng, X Chen, D Wu, L Gan, B Yang, C Fu, Y Wu, Y Cao Interleukin-20 Acts as a Promotor of Osteoclastogenesis and Orthodontic Tooth Movement Stem Cells International, 2021-05-26;2021(0):5539962. 2021-05-26 [PMID: 34122555] (Bioassay, Rat)
• Y Zeng, M Zhou, L Chen, H Fang, S Liu, C Zhou, J Sun, Z Wang Alendronate loaded graphene oxide functionalized collagen sponge for the dual effects of osteogenesis and anti-osteoclastogenesis in osteoporotic rats Bioact Mater, 2020-06-25;5(4):859-870. 2020-06-25 [PMID: 32637749] (Cell Culture, Rat)
• Q Tang, Z Hu, H Jin, G Zheng, X Yu, G Wu, H Liu, Z Zhu, H Xu, C Zhang, L Shen Microporous polysaccharide multilayer coated BCP composite scaffolds with immobilised calcitriol promote osteoporotic bone regeneration both in vitro and in vivo Theranostics, 2019-01-30;9(4):1125-1143. 2019-01-30 [PMID: 30867820] (Bioassay, Rat)

Bioinformatics

• Uniprot:
  • XP_008769150()